8-K: Mustang Bio Announces Full-Year 2023 Financial Results and Provides Corporate Update

Mustang Bio reported its full-year 2023 financial results, highlighting progress in its clinical programs and strategic corporate activities.

Summary

• Mustang Bio announced its financial results for the year ended December 31, 2023, with a net loss of $51.6 million, or $6.00 per share, compared to a net loss of $77.5 million, or $10.09 per share, in 2022.
• The company's cash and cash equivalents decreased significantly to $7.0 million from $76.7 million year-over-year, primarily due to a $30.4 million debt payment.
• Research and development expenses decreased to $40.5 million in 2023 from $62.5 million in 2022.
• General and administrative expenses also decreased to $9.7 million from $12.2 million in the previous year.
• Mustang Bio sold its manufacturing facility to uBriGene for an upfront payment of $6 million, with a potential additional $5 million contingent payment.
• The company completed a registered direct offering in October 2023, raising approximately $4.4 million in gross proceeds.
• Mustang plans to initiate a registrational CAR-T trial for relapsed or refractory Waldenstrom macroglobulinemia in the second half of 2024, with potential topline results in the second half of 2026.
• The company is also evaluating a Phase 1 multicenter clinical trial for MB-109, a combination therapy for recurrent GBM and high-grade astrocytomas.

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical trial results and strategic advancements, balanced by significant financial challenges. The clinical data for MB-106 is very encouraging, and the company is moving forward with a registrational trial. However, the substantial decrease in cash reserves and the need for additional funding are concerning. Overall, the sentiment is cautiously optimistic.

Positives

• MB-106 demonstrated a 100% overall response rate in patients with follicular lymphoma and Waldenstrom macroglobulinemia.
• MB-106 showed a favorable safety profile with no high-grade cytokine release syndrome or neurotoxicity.
• The company is advancing a registrational trial for Waldenstrom macroglobulinemia, which has no FDA-approved CAR-T therapy.
• Mustang is exploring a novel combination therapy, MB-109, for recurrent GBM and high-grade astrocytomas.
• The company reduced its net loss from $77.5 million in 2022 to $51.6 million in 2023.
• Research and development expenses decreased from $62.5 million in 2022 to $40.5 million in 2023.
• General and administrative expenses decreased from $12.2 million in 2022 to $9.7 million in 2023.
• The company has a collaboration with the Mayo Clinic to progress its in vivo CAR-T technology platform.

Negatives

• Mustang Bio's cash and cash equivalents decreased significantly from $76.7 million to $7.0 million year-over-year.
• The company incurred a net loss of $51.6 million for the year ended December 31, 2023.
• The contingent payment from the sale of the manufacturing facility is subject to the company raising $10 million in gross proceeds from equity raises and the lease transfer being approved.
• The lease transfer to uBriGene is under review by the U.S. Committee on Foreign Investment in the United States (CFIUS).

Risks

• The company's ability to transfer the lease of its manufacturing facility and receive the contingent payment is uncertain.
• There are risks associated with the purchaser of the manufacturing facility performing its obligations under the manufacturing services agreement.
• The company faces risks related to the development stage of its product candidates and the timing of clinical trials.
• Mustang Bio is dependent on third-party suppliers and needs substantial additional funds.
• The company faces competition and risks related to government regulation and intellectual property matters.

Future Outlook

Mustang Bio plans to initiate a registrational CAR-T trial for Waldenstrom macroglobulinemia in the second half of 2024 and is evaluating a Phase 1 multicenter clinical trial for MB-109. The company anticipates the publication of proof-of-concept research for its in vivo CAR-T technology platform in 2024. They also expect the first patients to be treated in investigator-sponsored trials for XSCID in 2024.

Management Comments

• 2023 was an exciting year for Mustang filled with many highlights, including compelling interim data from Mustangs multicenter Phase 1/2 clinical trial of MB-106.
• We believe the CAR T-cell persistence of up to 3 years in the original single institution trial at Fred Hutch and up to 1 year in the current Mustang-sponsored multicenter trial are important potential contributors to the deepening and durability of responses.
• We plan to move ahead with the first ever registrational CAR-T trial focused on relapsed or refractory Waldenstrom macroglobulinemia.
• We expect to treat the first patient in the second half of 2024, which could enable topline results in the second half of 2026.
• We are evaluating the potential to initiate a first-ever Phase 1 multicenter clinical trial at City of Hope (COH) and the University of Alabama at Birmingham (UAB) to assess the safety, tolerability and efficacy of MB-109.

Industry Context

The announcement highlights Mustang Bio's progress in the competitive field of cell and gene therapies, particularly in CAR-T therapy for hematologic malignancies and solid tumors. The focus on Waldenstrom macroglobulinemia, a disease with no FDA-approved CAR-T therapy, positions Mustang as a potential leader in this space. The company's efforts to combine CAR-T therapy with oncolytic viruses for solid tumors also reflect a growing trend in the industry.

Comparison to Industry Standards

• The 100% overall response rate for MB-106 in follicular lymphoma and Waldenstrom macroglobulinemia is very promising and compares favorably to other CAR-T therapies in similar indications, such as those from Gilead (Yescarta) and Novartis (Kymriah), although direct comparisons are difficult due to different trial designs and patient populations.
• The reported CAR-T cell persistence of up to 3 years in the Fred Hutch trial and up to 1 year in the Mustang-sponsored trial is notable, as durability of response is a key challenge in CAR-T therapy.
• The planned registrational trial for Waldenstrom macroglobulinemia is significant, as there are currently no FDA-approved CAR-T therapies for this indication, setting Mustang apart from competitors.
• The combination approach of MB-109, using an oncolytic virus to enhance CAR-T efficacy, is an innovative strategy that aligns with the industry's focus on overcoming tumor microenvironment resistance, similar to approaches being explored by companies like BioNTech and Regeneron.
• The financial situation of Mustang Bio, with a significant decrease in cash reserves, is a concern and highlights the capital-intensive nature of the biotech industry, similar to many other clinical-stage companies.

Stakeholder Impact

• Shareholders may be encouraged by the positive clinical trial results and the advancement of key programs, but concerned about the company's financial position.
• Employees may be affected by the sale of the manufacturing facility and the ongoing discussions with CFIUS.
• Patients with Waldenstrom macroglobulinemia and other cancers may benefit from the development of new therapies.
• Suppliers and creditors may be impacted by the company's financial situation and strategic changes.

Next Steps

• Mustang plans to request Regenerative Medicine Advanced Therapy (RMAT) designation for indolent lymphoma in the first half of 2024.
• The company expects to treat the first patient in the registrational CAR-T trial for Waldenstrom macroglobulinemia in the second half of 2024.
• Mustang is evaluating plans to initiate a Phase 1 multicenter clinical trial for MB-109.
• The company anticipates the publication of proof-of-concept research for its in vivo CAR-T technology platform in 2024.
• The first patients are expected to be treated in investigator-sponsored trials for XSCID in 2024.

Key Dates

Keywords

CAR-T therapy, Waldenstrom macroglobulinemia, Follicular lymphoma, Glioblastoma, MB-106, MB-109, Clinical trial, Biopharmaceutical, Cell therapy, Gene therapy, RMAT designation, Financial results